Cardiac amyloidosis is serious condition characterized by the deposition of abnormal proteins called amyloids in the heart tissue. It can lead to progressive heart failure and other cardiovascular complications. Managing cardiac amyloidosis requires a multidisciplinary approach involving various medical specialists.
Recognize the Signs meeting on Cardiac Amyloidosis provide HCPs with valuable insights into the ATTR-CM patient journey. Starting from suspension, diagnosis and ending by the management.
By staying updated through these educational sessions, medical professionals can enhance their ability to provide optimal care to patients with cardiac amyloidosis.
Date: 16th September, 2023
Time: 10:00 AM (GMT+3)
This image is for representation purposes only
PP-UNP-SAU-0298
We provide treatment insights, medicine information to support healthcare professionals.
Medical Information is here to support you with your product information inquiries.
Information relating to specific disease areas aligned to Pfizer's portfolio
Search through our scientific database and find the response to your Medical Information enquiry on a Pfizer product.
Subscribe to receive a comprehensive and timely compilation of the latest scientific journal articles on various therapy areas.
A global program designed to empower HCPs to deliver better patient outcomes through access to important and relevant educational content.
Browse and register for speaker programs
View resources for you and your patients
Find videos and on-demand webinars
Explore selected congresses, congress materials, therapeutic and disease areas.
Pfizer Medical Information is here to support you with your product medical inquiries.
Report Adverse Events
Please send us an email if you want to report an adverse event, email your enquiry to [email protected]
Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.